{"title":"Transcatheter edge-to-edge repair in patients with mitral annular calcification: A systematic review and meta-analysis.","authors":"Abiodun Idowu, Olayinka Adebolu, Bakhtawer Siraj, Phuuwadith Wattanachayakul, Omotola Balogun, Kevin Bryan Lo, Christian Witzke, Emmanuel Akintoye, Behnam Bozorgnia, Gregg Pressman","doi":"10.1016/j.amjms.2025.07.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mitral annular calcification (MAC) is common in patients with functional mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair (TEER). However, the safety and effectiveness of TEER systems in patients with MAC is poorly understood.</p><p><strong>Methods: </strong>We systematically reviewed multiple online databases to identify studies that reported outcomes in patients undergoing TEER with underlying moderate/severe MAC versus those with no/mild MAC. Random-effect model meta-analysis at a 95 % confidence interval was done via Cochrane Review Manager 5.4.</p><p><strong>Results: </strong>A total of 6 studies with a pooled 2808 patients (no/mild MAC: 84.5 % vs moderate/severe MAC: 15.5 %) were included. Compared to those with no/mild MAC, patients undergoing TEER with moderate/severe MAC have an insignificant trend towards a lower immediate procedural success (OR: 0.62, 95 % CI: 0.37 - 1.04, p = 0.07). After one year of TEER, the two groups had similar rates of repeat mitral valve intervention or surgery (OR: 1.67, 95 %CI: 0.92 - 3.05, p = 0.09), sustained clinical improvement (NYHA ≤ 2) (OR: 0.86, 95 %CI: 0.64 - 1.15, p = 0.30), and heart failure re-admission (OR: 0.84, 95 %CI: 0.52 - 1.36, p = 0.48). All-cause mortality was, however, higher in the moderate/severe MAC patients (OR: 1.82, 95 %CI: 1.15 - 2.86, p = 0.01).</p><p><strong>Conclusions: </strong>TEER appears safe and effective in carefully selected patients with significant MAC. A standardized selection algorithm is needed to identify MAC patients that would benefit most from TEER.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2025.07.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Mitral annular calcification (MAC) is common in patients with functional mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair (TEER). However, the safety and effectiveness of TEER systems in patients with MAC is poorly understood.
Methods: We systematically reviewed multiple online databases to identify studies that reported outcomes in patients undergoing TEER with underlying moderate/severe MAC versus those with no/mild MAC. Random-effect model meta-analysis at a 95 % confidence interval was done via Cochrane Review Manager 5.4.
Results: A total of 6 studies with a pooled 2808 patients (no/mild MAC: 84.5 % vs moderate/severe MAC: 15.5 %) were included. Compared to those with no/mild MAC, patients undergoing TEER with moderate/severe MAC have an insignificant trend towards a lower immediate procedural success (OR: 0.62, 95 % CI: 0.37 - 1.04, p = 0.07). After one year of TEER, the two groups had similar rates of repeat mitral valve intervention or surgery (OR: 1.67, 95 %CI: 0.92 - 3.05, p = 0.09), sustained clinical improvement (NYHA ≤ 2) (OR: 0.86, 95 %CI: 0.64 - 1.15, p = 0.30), and heart failure re-admission (OR: 0.84, 95 %CI: 0.52 - 1.36, p = 0.48). All-cause mortality was, however, higher in the moderate/severe MAC patients (OR: 1.82, 95 %CI: 1.15 - 2.86, p = 0.01).
Conclusions: TEER appears safe and effective in carefully selected patients with significant MAC. A standardized selection algorithm is needed to identify MAC patients that would benefit most from TEER.